Jean-Frederic Colombel, DDW 2022: U-EXCEED Phase 3 Study – Upadacitinib for Moderate to Severe Crohn’s Disease

touchIMMUNOLOGY caught up with Prof. Jean-Frederic Colombel (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to discuss the objectives, design and findings from the U-EXCEED phase 3 study, investigating upadacitinib induction therapy in moderate to severe crohn’s disease.

The abstract ‘EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE WHO FAILED PRIOR BIOLOGICS: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEED STUDY.’ was presented at Digestive Disease Week 2022, May 21-24, 2022.

Questions

1. What is the mechanism of action of upadacitinib? (0:24)
2. What were the objectives, design and eligibility criteria of the U-EXCEED study? (2:08)
3. What were the clinical endpoints and how well were they achieved? (3:18)
4. What questions remain unanswered and what future studies are planned? (4:02)

Disclosures: Jean-Frederic Colombel discloses consulting for AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi, Takeda, TiGenix and Vifor; receiving grant/ research support from AbbVie, Janssen Pharmaceuticals and Takeda; serving on advisory boards for AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi, Takeda, TiGenix and Vifor; receiving honoraria from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi, Takeda, TiGenix and Vifor; and is a stock shareholder in Intestinal Biotech Development. 

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of DDW 2022.